QIAGEN (QGEN) “announced a new commercial partnership and co-marketing agreement with ID Solutions, a French provider of high-quality digital PCR assays and customized molecular testing solutions for oncology and other disease areas, to expand the availability of dPCR assays for oncology research applications. The combination of QIAGEN’s global reach and automation expertise with the assay development and manufacturing capabilities of ID Solutions will strengthen QIAGEN’s position in oncology research. Under the agreement, ID Solutions will manufacture and supply dPCR assays for non-clinical research use on QIAGEN’s QIAcuity platforms. These assays are optimized to simultaneously detect multiple mutations in cell-free DNA from plasma and genomic DNA from formalin-fixed, paraffin-embedded tissue. QIAGEN will commercialize these kits starting in Europe as the first region, with the potential for future expansion into other regions.”
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QGEN:
- Citi opens ‘upside 90-day short-term view’ on Qiagen
- Cautious Optimism for Qiagen Amidst Industry Challenges: Awaiting Long-term Growth Assurance
- Qiagen’s Strong Positioning and Growth Potential Earns Buy Rating from Analyst
- Qiagen Receives Notification of BlackRock’s Voting Rights
- Qiagen’s Voting Rights Announcement Highlights BlackRock’s Influence